Answer
Aug 08, 2025 - 10:15 AM
DUPIXENT (dupilumab) is primarily approved for conditions like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. However, recent studies have been exploring its potential use for chronic obstructive pulmonary disease (COPD), particularly in patients with elevated eosinophil levels. While some findings suggest it may offer benefits for a subset of COPD patients, it is not yet widely approved for this use, and further research is needed to fully establish its efficacy and safety for COPD.
